Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Amy R. Tso
Third Circuit Affirms Rejection Of AstraZeneca's Challenges To IRA Drug Price Negotiation Program
On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district court's dismissal of AstraZeneca's challenges to the Inflation Reduction Act's Drug Price Negotiation Program and CMS's Guidance implementing the Program. AstraZeneca manufactures Farxiga, one of the drugs selected in the first round of drug price negotiations under the Program. Farxiga (dapagliflozin) is used to treat diabetes, heart disease, and kidney disease.
Third Circuit Affirms Rejection of AstraZeneca’s Challenges to IRA Drug Price Negotiation Program | JD Supra
On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district court’s dismissal of AstraZeneca’s challenges to the Inflation Reduction Act’s Drug Price Negotiation Program and CMS’s Guidance implementing the Program. AstraZeneca manufactures Farxiga, one of the drugs selected in the first round of drug price negotiations under the Program. Farxiga (dapagliflozin) is used to treat diabetes, heart disease, and kidney disease.
Third Circuit Affirms Rejection of AstraZeneca’s Challenges to IRA Drug Price Negotiation Program
On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district court’s dismissal of AstraZeneca’s challenges to the Inflation Reduction Act’s Drug Price Negotiation Program and CMS’s Guidance implementing the Program. AstraZeneca manufactures Farxiga, one of the drugs selected in the first round of drug price negotiations under the Program. Farxiga (dapagliflozin) is used to treat diabetes, heart disease, and kidney disease.
A MPET2-mPBPK model for subcutaneous injection of biotherapeutics with different molecular weights: From local scale to whole-body scale
An effective drug delivery approach of biotherapeutics is essential in the treatment of numerous diseases [1], such as migranies [2], cancers [3], [4], and psoriasis [5]. The COVID-19 pandemic has further intensified the demand of an efficient drug administration approach for large-molecule therapeutic antibodies (mAbs) [6], [7], [8], [9], [10]. Subcutaneous injection has attracted unprecedented attention due to its low cost and low risk of systemic infection [11], [12], [13], [14], [15].
Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches
Research Letter October 2017 JAMA Neurol. 2017;74(10):1266-1267. doi:10.1001/jamaneurol.2017.2122 Trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders that are characterized by attacks of unilateral pain of varying duration and prominent, ipsilateral cranial autonomic symptoms, such as lacrimation, conjunctival injection, nasal congestion, rhinorrhea, or periorbital edema.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Amy R.
Contact Amy R., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack